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Abstract
Background: Although oral hypoglycemic agents (OHAs) are an essential element of therapy for the management
of type 2 diabetes, OHA adherence is often suboptimal. Pharmacists are increasingly being integrated into primary
care as part of the move towards a patient-centered medical home and may have a positive influence on
medication use. We examined whether the presence of pharmacists in primary care clinics was associated with
higher OHA adherence.
Methods: This retrospective cohort study analyzed 280,603 diabetes patients in 196 primary care clinics within the
Veterans Affairs healthcare system. Pharmacists presence, number of pharmacist full-time equivalents (FTEs), and the
degree to which pharmacy services are perceived as a bottleneck in each clinic were obtained from the 2007 VA
Clinical Practice Organizational Survey—Primary Care Director Module. Patient-level adherence to OHAs using
medication possession ratios (MPRs) were constructed using refill data from administrative pharmacy databases
after adjusting for patient characteristics. Clinic-level OHA adherence was measured as the proportion of patients
with MPR >= 80%. We analyzed associations between pharmacy measures and clinic-level adherence using linear
regression.
Results: We found no significant association between pharmacist presence and clinic-level OHA adherence.
However, adherence was lower in clinics where pharmacy services were perceived as a bottleneck.
Conclusions: Pharmacist presence, regardless of the amount of FTE, was not associated with OHA medication
adherence in primary care clinics. The exact role of pharmacists in clinics needs closer examination in order to
determine how to most effectively use these resources to improve patient-centered outcomes including
medication adherence.
Keywords: Pharmacist, Medication adherence, Diabetes mellitus, Oral hypoglycemic agent, Patient-centered
medical home
Background
Oral hypoglycemic agents (OHA) are a therapeutic
mainstay for type 2 diabetes patients with mild to mod-
erate disease [1]. However, a systematic review of 20
studies indicated that OHA adherence rates range from
36-93% [2]. More recent studies have found that 65-78%
of patients have an adherence rate of greater than 80%
for oral hypoglycemic agents, which is a commonly
accepted threshold for clinical effectiveness [1,3,4].
Tasks typically done by clinical pharmacists, including
following a diabetes care algorithm [5], diabetes educa-
tion, medication counseling, education about home glu-
cose monitoring [6,7], adjustment of hypoglycemic
regimens [6] and patient refill reminders, [8] have all
been associated with improved medication adherence. A
systematic review found that pharmacist-provided pa-
tient care was associated with reductions in hemoglobin
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A1c, LDL cholesterol, blood pressure and adverse drug
events [9]. However, these studies usually evaluated spe-
cific pharmacy-based interventions rather than the influ-
ence of pharmacists in uncontrolled, “real-world”
primary care practices.
Like many health systems nationally, the Veterans
Health Administration (VA) is undergoing a major
transformation of primary care to team-based care, by
implementing a patient centered medical home (PCMH)
model system wide [10,11] to improve access, coordin-
ation, and continuity of care. Pharmacists have been
recommended as a standard component of patient-
centered medical homes [12], but their impact on OHA
adherence has not been studied. Pharmacists in VA pri-
mary care clinics may have a clinically oriented role by
providing counseling and education to patients taking
diabetes medications. However, pharmacists in VA may
also be limited to a purely dispensing role or simultan-
eously manage both clinical and dispensing tasks. VA is
a particularly good system for studying this question due
to its nationally integrated computerized patient medical
records, including pharmacy refill information, which
provides an estimate for medication adherence. In VA,
primary care is provided through clinics based at VA
hospitals and their affiliated community based outpatient
clinics [13]. A VA parent hospital and its affiliated
community clinics share the management structure and
support, such as administration, feedback regarding
treatment quality, and centralized support for care
management.
The purpose of this study was to examine whether the
presence of pharmacists in VA primary care clinics was
associated with improved adherence to OHAs among
patients with type 2 diabetes. We hypothesized that the
proportion of patients within a primary care clinic who
would be adherent to OHAs was higher when a pharma-
cist was present, since these staff would be able to focus
on barriers to obtaining refills and improvements in ad-
herence counseling. We also examined the relationship
between the degree of bottleneck in pharmacy services
at the primary care clinics as reported by directors
of primary care clinics and clinic-level medication
adherence.
Methods
Data
This study used data from VA’s national administrative
and pharmacy databases linked with a national survey of
196 primary care clinics focused on staffing and
organizational barriers to care. Patient demographics,
diagnoses, and utilization data from Fiscal Years (FYs)
2005–2007 were obtained from the VA Vital Status File,
and medication adherence measures were constructed
using pharmacy records from the FY2007 Decision
Support System (DSS) National Outpatient Pharmacy
Extracts. All data were measured prior to VA’s imple-
mentation of PCMH in April 2010.
To assess whether the integration of pharmacy staff in
primary care clinics, as indicated by the PCMH model,
improves adherence to OHAs, we obtained data on
pharmacist presence and the number of full-time
equivalent (FTE) pharmacists in a clinic from the 2007
Veterans Health Administration (VHA) Clinical Practice
Organizational Survey—Primary Care Director Module
[14]. The survey was sent to 250 VA primary care clinics,
which included 153 hospital-based clinics and 97
community-based satellite clinics. The overall survey re-
sponse rate was 93% [14,15]. Our study sample included
196 clinics that provided complete responses to the ques-
tions about pharmacists and pharmacy services. Human
Subjects approval was obtained from Seattle, Durham and
Ann Arbor VA Medical Centers.
Study sample
Patients with type 2 diabetes were identified using a pre-
viously validated algorithm based on two or more out-
patient or one inpatient diabetes related ICD-9 diagnosis
in FY2005 or FY2006 [16]. Users of OHAs, including
sulfonylureas, metformin, and thiazolidinediones, were
defined as those who had at least two non-partial (>30
day) fills of the same OHA in FY2006. Selection of these
three OHAs was driven by the VA formulary and consti-
tuted over 98% of all OHA prescriptions in VA. For
inclusion in our study, patients were required to be non-
institutionalized, prescribed at least one class of OHA,
and be alive through the end of FY2007. Patients were
excluded if they were prescribed any insulin except neu-
tral protamine Hagedorn (NPH) to remove those who
may have transitioned to insulin therapy during the ob-
servation period. We did not exclude patients on NPH
insulin because it was frequently used as an adjunct to
oral therapy. Further exclusion criteria included: patients
with a nursing home or extended hospital stay in
FY2007, patients seen in VA clinics outside the contin-
ental United States, or patients treated at VA contracted
clinics. If patients were seen at multiple VA primary care
clinics, they were assigned to the one with the most vis-
its or, if the numbers of visits were equal, were randomly
assigned to one of the clinics. The final study sample
included 280,603 diabetes patients who received care
from 196 primary clinics for which data were also avail-
able from the primary care survey. These patients were a
subset of a sample documented in a prior study [17].
Adjusted clinic-level medication adherence
Adherence to OHAs was estimated at the patient level
using ReComp, a validated medication-possession ratio
(MPR) algorithm described previously [18,19]. MPR has
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been shown to be correlated with hemoglobin A1c
values in patients with diabetes [20]. Adherence was
measured for each class of OHA in 90-day increments
for all of FY2006 and FY2007 and the adherence values
for the first quarter of FY2007 were used as the
dependent variable. The 90-day time period was chosen
since refill adherence for this 90-day duration is asso-
ciated with physiologic outcomes [18]. Patients were
considered adherent if they had medication available for
80 percent or more of the period, i.e., MPR>=80%. If
patients were taking more than one OHA, the propor-
tion of days covered during the period for each medica-
tion class was averaged into an overall adherence value.
For example, a patient on both metformin and a sulfony-
lurea who had three 30-day fills (100%) of the sulfony-
lurea with one 30-day fills (33%) of metformin would
have an average adherence score of 66.5%, which would
be considered nonadherent to the overall regimen.
Patients in VA obtain medication refills by either phon-
ing the pharmacy, using an online patient portal (My
HealtheVet), using automated calling systems, or making
a clinic appointment.
Clinic-level adherence measures were then calculated
based on the proportion of OHA adherent patients
within a clinic. For example, if 140 of 200 patients in a
clinic had 80% or greater adherence, then the clinic
would have an adherence rate of 70%. To account for
differences in patient characteristics across clinics that
might influence clinic-level adherence scores, we risk
adjusted clinic-level adherence scores using a hierarch-
ical logistic regression model (see Wong, Piette et al.
[17] for more details). Specifically, the model first esti-
mated adherence at the patient level adjusting for pa-
tient characteristics known to impact adherence such as
race and the presence of comorbid depression. Random
intercepts were also included for parent hospitals and
primary care clinics affiliated (i.e., nested) with each par-
ent hospital to account for other facility characteristics
that might influence adherence, such as the presence of
automated phone systems for prescription refills. Pre-
dicted clinic-level adherence was then obtained from the
patient-level model using the mean characteristics for a
given clinic.
Measuring the role of pharmacists in the clinic
We used four measures, including presence of pharma-
cists, two pharmacist FTEs measures, and perception of
pharmacy services as a bottleneck in primary care
clinics, derived from the VHA Clinical Practice
Organizational Survey.
Questions pertaining to the role of the pharmacist
were completed by the primary care director at each
clinic. In the survey, respondents were asked:
“Which of the following types of clinicians or other
staff are included as members of your primary care
program?”
with “pharmacists” among the listed options. If pharma-
cists were indicated, respondents were asked:
“What is the combined total of whole and part full-
time equivalent employees (FTEs) currently allocated
to your primary care program for this type of
clinician?”
For the current study, we measured the availability of
pharmacists in each clinic in three ways: 1) a binary vari-
able indicating whether any pharmacists were noted in
the survey as included in the primary care program; 2)
pharmacist FTE per 10,000 primary care patients to ac-
count for clinic size; and 3) pharmacist FTE per 100,000
primary care patient encounters to account for clinic
workload.
For the perception of pharmacy services, respondents
were asked:
“To what extent are each of the following a patient
flow ‘bottleneck’ for your primary care clinic?”
with “Pharmacy services” among the list of services.
Questions regarding bottlenecks in primary clinics were
adapted from clinic manager surveys administered by
the Minimizing Error, Maximizing Outcome Study [21].
In their study, questions measuring the degree of bottle-
neck in different areas of a primary care clinic were
asked after physicians pointed out process factors affect-
ing quality and errors during focus groups [21,22]. These
factors included inadequate resources, ambiguous or
nonexistent policies, poor communication and errors in
information systems [23]. We constructed a categorical
measure of the pharmacy as a perceived bottleneck using
the response options “little/no extent,” “some extent,”
“moderate extent”, and “large extent”. We included all
clinics because patients receiving primary care at clinics
with no pharmacist have alternative means of obtaining
medications from VA. However, none of these measures
could delineate the exact role of pharmacists in primary
care clinics (i.e. anticoagulation management, medica-
tion titration for chronic diseases such as hypertension
and diabetes, patient medication counseling, facilitation
of refills, patient consultation, etc.).
Statistical analysis
The level of analysis was the clinic (n=196). We per-
formed ordinary least squares (OLS) regression with
adjusted clinic-level medication adherence, i.e., propor-
tion of OHA adherent patient in a clinic, as the outcome
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variable and pharmacist availability as the exposure of
interest. Four separate analyses were performed, one for
each of four different measures of pharmacist exposure
described above.
Several auxiliary analyses were performed to evaluate
model robustness and sensitivity to characteristics of the
sample. Community-based clinics were significantly
more likely to report having pharmacists than hospital-
based clinics, therefore we performed sensitivity analysis
of the effect of pharmacist availability separately within
those two clinic-type subgroups. Results were similar, so
we report the pooled sample results below. We also per-
formed a sensitivity analysis using a 1-year adherence
measure with similar results using a 90-day adherence
measure, therefore we presented the results of 90-day
adherence in this paper. We performed the Breusch-
Pagan test [24] of heteroskedasticity to determine if
clinic size affected the error variance, and found no evi-
dence of heteroskedasticity. Also, a post-hoc power ana-
lysis by simulation [25] was performed to determine our
statistical power to discern an effect of pharmacist
presence in OLS models. Results indicated that with a
sample of 196 clinics, assuming an alpha level of 0.05
(two-tailed) and a 1% effect size for clinic-level adher-
ence, the estimated power was greater than 99%. For an
assumed effect size of 0.5%, the estimated power was
95.5%. All analyses were performed using SAS Version
9.2 (SAS Corporation, Cary, NC USA).
Results
Descriptive statistics of adherence and pharmacist
resources in primary care clinics
Among the 196 clinics, the number of patients with dia-
betes ranged from 241 to 7,399. Community based
clinics on average had fewer diabetes patients than
hospital-based clinics (1,019 versus 1,641, p<0.001). The
average adjusted clinic-level adherence to OHAs was
70.7% and ranged from 57.5% to 79.1%. The average
adjusted clinic-level adherence for primary care clinics
with and without a pharmacist was 70.4% and 71.3%,
respectively. Pharmacists were present in 70.4% of pri-
mary care clinics, with no significant difference in
pharmacist availability between hospital-based clinics
and community-based clinics (67.7% versus 75.8%,
p=0.245). For those clinics that reported having a
pharmacist, the average pharmacist FTE was 3.13 and
ranged from 0.2 to 13 (Standard Deviation (SD)=2.43).
Descriptive statistics of patients in primary care clinics
Patients were predominantly older and male (Table 1).
The average number of primary care visits per year was
3.9. The two most common comorbidities were hyper-
tension (64.1%) and coronary artery disease (19.1%).
Patients seen in clinics with a pharmacist differed from
those seen in clinics without a pharmacist across a
number of characteristics including race and incidence
of chronic obstructive pulmonary disease and post-
traumatic stress disorder.
Regression results
The model testing the effect on adherence of any
pharmacist presence showed no statistically significant
relationship (p=0.227). When adjusting for clinic size,
pharmacist FTE per 10,000 primary care patients
(p=0.494) and pharmacist FTE per 100,000 primary care
encounters (p=0.723) were also not associated with
clinic-level adherence (Table 2, Figures 1 and 2). The
amount of variation in clinic-level adherence explained
by pharmacist presence or pharmacist FTE was small
with R-squared values ranging from 0.0009 to 0.0074.
All results were similar when examining community-
based and hospital-based clinics separately.
Pharmacy bottleneck
Of the 196 clinics in our sample, those where pharmacy
services were perceived as a bottleneck had poorer ad-
herence (Wald statistic for trend, p=0.004). Adherence
scores for clinics with a high degree of bottleneck
(p=0.010), a moderate degree of bottleneck (p=0.031)
and a small degree of bottleneck (p=0.057) were
lower compared to clinics with little or no bottleneck
(Table 2, Figure 3). The amount of variation in clinic-
level adherence explained by pharmacy bottleneck mea-
sures was 4.2%.
Discussion
This study assessed the association between the presence
of pharmacists and the proportion of diabetes patients
adherent to OHAs within VA primary care clinics. The
results indicate that adherence scores are not signifi-
cantly better within clinics that have a pharmacist
present, regardless of the amount of FTE pharmacist
staff available. However, the perception of pharmacy
services as a bottleneck was associated with lower clinic-
level medication adherence. While the percent of vari-
ation in clinic-level adherence explained by each
pharmacy measure was generally small (< 5%), relative
to pharmacist presence measures, the perception of the
pharmacy as a bottleneck had substantially greater ex-
planatory power.
Our clinic-level findings generally differ from prior
patient-level studies demonstrating the value of having
pharmacists present in primary care clinics [9,26-29].
Most often, these studies evaluated a specific function or
task related to the pharmacist as a mechanism for im-
proving diabetes care. In contrast, the current study eval-
uated pharmacist presence and therefore characterizes
their impact on adherence in more “real world” settings.
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As the structure of clinics changes towards a multi-
disciplinary team approach using the PCMH, there will
be an increasing component of healthcare provided by
the non-physician care management team [30]. The
PCMH calls for pharmacists to be part of this team and
pharmacists have been included in prior PCMH demon-
stration projects [31]. The goals of including pharmacists
in the PCMH are to optimize medication regimens,
improve management of chronic diseases, and lower
barriers to adherence through assisting in refilling and
renewal of medications [12,32]. VA is working towards
complete implementation of a PCMH within all primary
care clinics and has routinely included pharmacists
in primary care clinics since 2010 [33]. Our results
suggest that without a clearly defined role, simply in-
cluding pharmacists in clinics may not improve adher-
ence to OHAs.
As in other healthcare systems, several organizational
factors in VA that are beyond pharmacists influence
may contribute to adherence problems. For example,
barriers in refilling medications could potentially miti-
gate the benefits of pharmacists. These barriers include
trouble getting through on phone lines [34], lower
health related internet use among veterans living in
rural locations [35], and difficulty getting to clinics
[36,37]. Although the role of a pharmacist in the
PCMH model should ideally include helping to de-
crease barriers to accessing or refilling medications,
pharmacists may currently have much different job
functions. For example, if pharmacists are staffing anti-
coagulation clinics, spending time dispensing medica-
tions, or completing other such tasks, then they will
not have the ability to engage in activities such as
medication education and counseling which have been
shown to positively impact medication adherence for
patients with diabetes.
Table 1 Descriptive statistics of study sample
Measure Overall Pharmacist in clinic
YES NO
Clinic Characteristics
# Clinics 196 138 58
Community-based
Clinic (%)
33.7 36.2 27.6
Study subjects per facility
(mean/SD)
1,432 (870) 1,457 (891) 1,370 (822)
Minimum 241 241 253
Maximum 7,399 7,399 4,262
Total patients per facility
(mean/SD)
28,162
(18,973)
28,873
(19,397)
26,469
(17,972)
Minimum 4,925 4,925 5,694
Maximum 108,694 108,694 90,024
Pharmacist FTE/10,000
clinic patients
1.03 (1.27) 1.46 (1.23) N/A
Pharmacist FTE/100K
patient encounters
1.63 (2.13) 2.31 (2.21) N/A
Patient Characteristics
# Subjects 280,603 201,127 79,476
Age (mean/SD) 67.4 (11.0) 67.3 (11.0) 67.5 (10.9)
Female (%) 2.3 2.3 2.2
Married (%) 63.9 63.1 65.9
White Race (%) 73.0 71.5 76.8
Free care due to
disability (%)
36.4 36.1 37.1
Free care due to low
income (%)
35.3 35.8 34.2
No free care (%) 28.3 28.1 28.7
DCSI Score (mean/SD) 3.8 (1.2) 3.8 (1.2) 3.8 (1.2)
Primary care visits
(mean/SD)
3.9 (3.0) 3.9 (3.1) 3.7 (2.8)
Total visits (mean/SD) 7.7 (9.7) 7.8 (10.0) 7.3 (8.8)
DCG Risk score
(mean/SD)
0.9 (0.6) 0.9 (0.6) 0.9 (0.6)
Cumulative in hospital
days (mean/SD)
0.2 (2.0) 0.2 (2.0) 0.2 (1.9)
Hospitalized during
FY06 Q4 (%)
2.8 2.8 2.9
Hypertension (%) 64.1 64.8 62.1
Peripheral vascular
disease (%)
1.3 1.3 1.3
Ischemic heart
disease (%)
19.1 19.1 19.2
Myocardial Infarction (%) 1.3 1.3 1.4
Stroke (%) 2.5 2.6 2.1
Other cerebrovascular
disease (%)
1.0 1.1 1.0
Chronic obstructive
pulmonary disease (%)
7.6 7.4 8.1
Congestive heart failure (%) 4.0 3.9 4.3
Chronic renal failure (%) 2.6 2.7 2.3
Table 1 Descriptive statistics of study sample (Continued)
Atrial fibrillation or
flutter (%)
6.1 6.1 6.0
Dementia (%) 1.0 1.0 0.9
Alcohol abuse (%) 2.1 2.0 2.1
Drug Abuse (%) 7.1 7.0 7.5
Post-traumatic stress
disorder (%)
7.2 7.4 6.8
Depression (%) 8.8 8.8 8.7
Schizophrenia (%) 1.7 1.8 1.6
Other mental illness (%) 1.7 1.8 1.6
Warfarin (%) 6.2 6.1 6.4
NPH insulin usage (%) 9.0 9.7 7.3
SD = Standard deviation; FTE = Full time equivalents; DCSI = Diabetes
complications severity index; DCG = Diagnostic cost group; NPH = Neutral
protamine Hagedorn; FY06 = Fiscal year; Q4 = Fourth quarter.
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The association between the degree of bottleneck in
pharmacy services and clinic-level medication adherence
suggests factors related to pharmacy services as per-
ceived by the primary care director impair the timely
dispensing of medications to patients. This result is
consistent with a prior study showing pharmacy pro-
cesses such as communication between inpatient dis-
charge team, outpatient physicians and pharmacists
were associated with a reduction in health care visits
and readmission [38]. Although prior studies have
shown the value of including pharmacists on general
medicine teams [36,39], our results suggest that the
mere presence of a pharmacist is not enough to improve
medication adherence. Instead, organization resources,
policies and procedures must be in place in order for
pharmacists to effectively perform job duties.
Our study has several strengths. Data were drawn
from a large, national administrative data system that
includes information on several important confounding
patient-level variables. The power for our study was
excellent, with a greater than 99% ability to detect a 1%
difference in clinic-level adherence between clinics with
and without a pharmacist. Also, we were able to link ad-
ministrative data to a nationwide clinic-level survey of
pharmacist availability that is rarely available in other
health systems and had a 93% response rate from 250
clinic representatives.
Several limitations exist in our study. First, we are un-
able to distinguish pharmacists based on variation across
clinics in their training, duties, or activities. If pharma-
cists have more clinically-oriented roles at some loca-
tions, but are limited to only dispensing medications at
other locations, then our findings are biased towards the
null hypothesis, masking potential pharmacist benefits in
facilities that have a more clearly defined adherence-
support role for their pharmacists. Future research
should also examine the exact roles of pharmacists
within VA and whether there is any association with
medication adherence based on specific clinical func-
tions. Second, the measures of pharmacist availability
Figure 1 Association between pharmacist full-time equivalents (FTE) per 10,000 primary care clinic patients and the proportion of
patients adherent in primary care clinics.
Table 2 Associations between clinic-level medication adherence and pharmacist presence and pharmacy is a
bottleneck
# Facilities Coefficient Pr > Chi-Sq R-Squared
Pharmacist in clinic
Pharmacist in clinic (0,1) 196 −0.0083 0.2269 0.0074
Pharmacist FTE per 10K patients, when FTE>0 138 −0.0021 0.4938 0.0034
Pharmacist FTE per 100K encounters, when FTE>0 138 −0.0006 0.7228 0.0009
Pharmacy is bottleneck (reference=no bottleneck)
Some extent 196 −0.0138 0.0570
Moderate extent 196 −0.0194 0.0310 0.0421
Large extent 196 −0.0296 0.0102
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and FTEs used in the study are reported by primary care
directors, but have not been validated. However, these
measures are the best that are currently available be-
cause administrative data do not indicate whether phar-
macists are specifically assigned to a primary care clinic.
Third, the number of community-based clinics reporting
the presence of a pharmacist was higher than we
expected, and some clinics may have reported on phar-
macists at parent VA facilities who may have little day to
day involvement in that community clinic. However, the
results remain the same when we conducted the analysis
including hospital-based clinics only, so we cannot
attribute the observed null findings exclusively to report-
ing on off-site pharmacists. Finally, this study was con-
ducted prior to the implementation of PCMH in VA.
Further studies should examine the functions of phar-
macists in that new primary care model.
Conclusions
In summary, the study shows that the proportion of
patients adherent to OHAs in VA primary care clinics
was not associated with the availability of pharmacists in
that clinic. However, pharmacy services perceived as bot-
tlenecked are associated with lower adherence. Our
Figure 2 Association between pharmacist full-time equivalents (FTE) per 100,000 primary care clinic patient visits and the proportion
of patients adherent in primary care clinics.
Trend Test P−value = 0.004
.
66
.
68
.
7
.
72
.
74
Ad
jus
ted
 P
rop
ort
ion
 of
 A
dh
ere
nt 
Pa
tie
nts
None Some Moderate Large
Degree of Pharmacy Bottleneck
95% Confidence Interval Proportion Adherent
Figure 3 Association between the perception of pharmacy services as a bottleneck and the proportion of patients adherent in primary
care clinics.
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results call for further research disentangling the role of
pharmacists in VA primary clinics and an examination
of how these roles can most efficiently affect patient out-
comes such as improved medication adherence.
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